Monocarbonyl curcumin analogues: Heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties

Journal of Medicinal Chemistry

Volumn 56, Issue 9, 2013, Pages 3456-3466

  Brown, Andrew ^a   Shi, Qi ^b   Moore, Terry W ^b   Yoon, Younghyoun ^a   Prussia, Andrew ^b   Maddox, Clinton ^a   Liotta, Dennis C ^b   Shim, Hyunsuk ^a   Snyder, James P ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CURCUMIN DERIVATIVE; HETEROCYCLIC COMPOUND; I KAPPA B KINASE BETA; PROTEIN KINASE B BETA; PROTEIN SERINE THREONINE KINASE INHIBITOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL MODIFICATION; DRUG BINDING SITE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME KINETICS; IC 50; INTRACELLULAR SIGNALING; MOLECULAR DOCKING; MOLECULAR MODEL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CURCUMIN; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MICE; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84877715497     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4002692     Document Type: Article

References (60)

1. Jurenka, J. S. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research Altern. Med. Rev. 2009, 14, 141
2. Perry, M. C.; Demeule, M.; Regina, A.; Moumdjian, R.; Beliveau, R. Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts Mol. Nutr. Food Res. 2010, 54, 1192
3. Lee, Y. K.; Park, S. Y.; Kim, Y. M.; Park, O. J. Regulatory effect of the AMPK-COX-2 signaling pathway in curcumin-induced apoptosis in HT-29 colon cancer cells Ann. N.Y. Acad. Sci. 2009, 1171, 489
4. Yang, C. L.; Liu, Y. Y.; Ma, Y. G.; Xue, Y. X.; Liu, D. G.; Ren, Y.; Liu, X. B.; Li, Y.; Li, Z. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway PLoS One 2012, 7, e37960
5. Aggarwal, B. B.; Surh, Y.-J.; Shishodia, S. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease; Springer Science+Business Media, LLC: New York, U.S., 2007.
6. Zhou, H.; Beevers, C. S.; Huang, S. The targets of curcumin Curr. Drug Targets 2010, 12, 332
7. Sharma, R. A.; Steward, W. P.; Gescher, A. J. Pharmacokinetics and pharmacodynamics of curcumin Adv. Exp. Med. Biol. 2007, 595, 453
8. Ji, J. L.; Huang, X. F.; Zhu, H. L. Curcumin and its formulations: potential anti-cancer agents Anti-Cancer Agents Med. Chem. 2011, 12, 210
9. Sun, S. H.; Huang, H. C.; Huang, C.; Lin, J. K. Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin Eur. J. Pharmacol. 2010, 690, 22-30
10. Epelbaum, R.; Schaffer, M.; Vizel, B.; Badmaev, V.; Bar-Sela, G. Curcumin and gemcitabine in patients with advanced pancreatic cancer Nutr. Cancer 2010, 62, 1137
11. Bayet-Robert, M.; Kwiatkowski, F.; Leheurteur, M.; Gachon, F.; Planchat, E.; Abrial, C.; Mouret-Reynier, M. A.; Durando, X.; Barthomeuf, C.; Chollet, P. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer Cancer Biol. Ther. 2010, 9, 8
12. Taylor, R. A.; Leonard, M. C. Curcumin for inflammatory bowel disease: a review of human studies Altern. Med. Rev. 2011, 16, 152
13. Gupta, S. C.; Patchva, S.; Aggarwal, B. B. Therapeutic roles of curcumin: lessons learned from clinical trials Am. Assoc. Pharm. Sci. J. 2013, 15, 195-218
14. National Institutes of Health. http://www.clinicaltrials.gov/ct2/results? term=curcumin&Search=Search (last accessed Feb 10, 2013).
15. Adams, B. K.; Ferstl, E. M.; Davis, M. C.; Herold, M.; Kurtkaya, S.; Camalier, R. F.; Hollingshead, M. G.; Kaur, G.; Sausville, E. A.; Rickles, F. R.; Snyder, J. P.; Liotta, D. C.; Shoji, M. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents Bioorg. Med. Chem. 2004, 12, 3871
16. Sun, A.; Lu, Y. J.; Hu, H.; Shoji, M.; Liotta, D. C.; Snyder, J. P. Curcumin analog cytotoxicity against breast cancer cells: exploitation of a redox-dependent mechanism Bioorg. Med. Chem. Lett. 2009, 19, 6627
17. Avonto, C.; Taglialatela-Scafati, O.; Pollastro, F.; Minassi, A.; Di Marzo, V.; De Petrocellis, L.; Appendino, G. An NMR spectroscopic method to identify and classify thiol-trapping agents: revival of michael acceptors for drug discovery? Angew. Chem., Int. Ed. 2011, 50, 467-471
18. Usta, M.; Wortelboer, H. M.; Vervoort, J.; Boersma, M. G.; Rietjens, I. M.; van Bladeren, P. J.; Cnubben, N. H. Human glutathione S-transferase-mediated glutathione conjugation of curcumin and efflux of these conjugates in Caco-2 cells Chem. Res. Toxicol. 2007, 20, 1895-1902
19. Wortelboer, H. M.; Usta, M.; van der Velde, A. E.; Boersma, M. G.; Spenkelink, B.; van Zanden, J. J.; Rietjens, I. M.; van Bladeren, P. J.; Cnubben, N. H. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin Chem. Res. Toxicol. 2003, 16, 1642-1651
20. Awasthi, S.; Pandya, U.; Singhal, S. S.; Lin, J. T.; Thiviyanathan, V.; Seifert, W. E., Jr.; Awasthi, Y. C.; Ansari, G. A. Curcumin-glutathione interactions and the role of human glutathione S-transferase P1-1 Chem.-Biol. Interact. 2000, 128, 19
21. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 2009, 9, 28-39
22. Kothari, V.; Wei, I.; Shanker, S.; Kalyana-Sundaram, S.; Wang, L.; Ma, L. W.; Vats, P.; Grasso, C. S.; Robinson, D. R.; Wu, Y. M.; Cao, X.; Simeone, D. M.; Chinnaiyan, A. M.; Kumar-Sinha, C. Outlier kinase expression by RNA sequencing as targets for precision therapy Cancer Discovery 2013, 3, 1-14
23. Adams, B. K.; Cai, J.; Armstrong, J.; Herold, M.; Lu, Y. J.; Sun, A.; Snyder, J. P.; Liotta, D. C.; Jones, D. P.; Shoji, M. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism Anti-Cancer Drugs 2005, 16, 263
24. Kasinski, A. L.; Du, Y.; Thomas, S. L.; Zhao, J.; Sun, S. Y.; Khuri, F. R.; Wang, C. Y.; Shoji, M.; Sun, A.; Snyder, J. P.; Liotta, D.; Fu, H. Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin Mol. Pharmacol. 2008, 74, 654
25. Thomas, S. L.; Zhao, J.; Li, Z.; Lou, B.; Du, Y.; Purcell, J.; Snyder, J. P.; Khuri, F. R.; Liotta, D.; Fu, H. Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy Biochem. Pharmacol. 2010, 80, 1309-1316
26. Olivera, A.; Moore, T. W.; Hu, F.; Brown, A. P.; Sun, A.; Liotta, D. C.; Snyder, J. P.; Yoon, Y.; Shim, H.; Marcus, A. I.; Miller, A. H.; Pace, T. W. Inhibition of the NF-kappaB signaling pathway by the curcumin analog, 3,5-bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties Int. Immunopharmacol. 2012, 12, 368
27. Yamaguchi, M.; Moore, T. W.; Sun, A.; Snyder, J. P.; Shoji, M. Novel curcumin analogue UBS 109 potently stimulates osteoblastogenesis and suppresses osteoclastogenesis: involvement in Smad activation and NF-κB inhibition Integr. Biol. 2012, 4, 905-913
28. Landis, I.; McCarroll, M.; Yang, C.; Sun, A.; Hiddingh, S.; Turker, M. S.; Snyder, J. P.; Hoatlin, M. E. Monoketone analogs of curcumin, a new class of potent Fanconi anemia pathway inhibitors Mol. Cancer 2009, 8 (133) 1-13
29. Thomas, S. L.; Zhong, D.; Zhou, W.; Malik, S.; Liotta, D.; Snyder, J. P.; Hamel, E.; Giannakakou, P. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1 Cell Cycle 2008, 7, 2409-2417
30. Zhu, S.; Moore, T. W.; Lin, X.; Morii, N.; Mancini, A.; Howard, R. B.; Culver, D.; Arrendale, R. F.; Reddy, P.; Evers, T. J.; Zhang, H.; Sica, G.; Chen, Z. G.; Sun, A.; Fu, H.; Khuri, F. R.; Shin, D. M.; Snyder, J. P.; Shoji, M. Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts Integr. Biol. 2012, 4, 633
31. Zhu, S.; Moore, T. W.; Snyder, J. P.; Shoji, M. Manuscript in preparation.
32. IPA, Ingenuity Systems, Inc. (1700 Seaport Blvd, 3rd Floor, Redwood City, CA 94063). http://www.ingenuity.com/ (accessed Sep 20, 2012).
33. Zhu, S.; Moore, T. W.; Lin, X.; Morii, N.; Mancini, A.; Howard, R. B.; Culver, D.; Arrendale, R. F.; Reddy, P.; Evers, T. J.; Zhang, H.; Sica, G.; Chen, Z. G.; Sun, A.; Fu, H.; Khuri, F. R.; Shin, D. M.; Snyder, J. P.; Shoji, M. Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts Integr. Biol. 2012, 4, 633
34. Chen, Y.; Craigen, W. J.; Riley, D. J. Nek1 regulates cell death and mitochondrial membrane permeability through phosphorylation of VDAC1 Cell Cycle 2009, 8, 257
35. Sa, G.; Das, T. Anti cancer effects of curcumin: cycle of life and death Cell Div. 2008, 3, 14
36. GraphPad Software, Inc., 2236 Avenida de la Playa, La Jolla, CA 92037, U.S.; http://www.graphpad.com/ (accessed Sep 20, 2012).
37. Compound 3 has also been shown to exhibit reversibility by the NMR method of Appendino et al.:(17) Moore, T.; Snyder, J. P. Unpublished results.
38. Suzuki, M.; Mori, M.; Niwa, T.; Hirata, R.; Furuta, K.; Ishikawa, T.; Noyori, R. Chemical implications for antitumor and antiviral prostaglandins: reaction of Δ7-prostaglandin A1 and prostaglandin A1 methyl esters with thiols J. Am. Chem. Soc. 1997, 119, 2376-2385
39. Yamakoshi, H.; Kanoh, N.; Kudo, C.; Sato, A.; Ueda, K.; Muroi, M.; Kon, S.; Satake, M.; Ohori, H.; Ishioka, C.; Oshima, Y.; Osada, H.; Chiba, N.; Shibata, H.; Iwabuchi, Y. KSRP/FUBP2 is a binding protein of GO-Y086, a cytotoxic curcumin analogue ACS Med. Chem. Lett. 2010, 1, 273-276
40. Serafimova, I. M.; Pufall, M. A.; Krishnan, S.; Duda, K.; Cohen, M. S.; Maglathlin, R. L.; McFarland, J. M.; Miller, R. M.; Frodin, M.; Taunton, J. Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles Nat. Chem. Biol. 2012, 8, 471-476
41. Lee, C.-U.; Grossmann, T. N. Reversible covalent inhibition of a protein target Angew. Chem., Int. Ed. 2012, 51, 8699-8700
42. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 2009, 9, 28-39
43. Hu, H.; Snyder, J. P. Models for predicting IKKA and IKKB blockade J. Chem. Inf. Model. 2012, 52, 310-3199
44. Yang, Q.; Lee, J.-D. Targeting the BMK1 MAP kinase pathway in cancer therapy Clin. Cancer Res. 2011, 17, 3527-3532
45. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat. Rev. Drug Discovery 2004, 3, 353
46. Fojo, T. Commentary: Novel therapies for cancer: why dirty might be better Oncologist 2008, 13, 277
47. Hopkins, A. L. Drug discovery: predicting promiscuity Nature 2009, 462, 167
48. von Eichborn, J.; Murgueitio, M. S.; Dunkel, M.; Koerner, S.; Bourne, P. E.; Preissner, R. PROMISCUOUS: a database for network-based drug-repositioning Nucleic Acids Res. 2011, 39, D1060
49. Lee, S. J.; Wang, J. Y. J. Exploiting the promiscuity of imatinib J. Biol. 2009, 8, 30.1-30.4
50. http://en.wikipedia.org/wiki/Imatinib (accessed Sep 21, 2012).
51. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 2006, 16, 127-136
52. Besnard, J.; Ruda, G. F.; Setola, V.; Abecassis, K.; Rodriguiz, R. M.; Huang, X.-P.; Norval1, S.; Sassano, M. F.; Shin, A. I.; Webster, L. A.; Simeons, F. R. C.; Stojanovski, L.; Prat, A.; Seidah, N. G.; Constam, D. B.; Bickerton, G. R.; Read, K. D.; Wetsel, W. C.; Gilbert, I. H.; Roth, B. L.; Hopkins, A. L. Automated design of ligands to polypharmacological profiles Nature 2012, 492, 215-222
53. http://www.discoverx.com/kinases/adp-quest-adp-quest-hs.php (accessed Sep 21, 2012).
54. http://www.millipore.com/catalogue/item/12-331 (accessed Sep 21, 2012).
55. http://www.invitrogen.com/site/us/en/home/Products-and-Services/ Applications/Drug-Discovery/Target-and-Lead-Identification-and-Validation/ KinaseBiology/Kinase-Activity-Assays/Z-LYTE.html?CID=fl-zlyte (accessed Sep 21, 2012).
56. http://www.invitrogen.com/site/us/en/home/Products-and-Services/Services/ custom-services/Screening-and-Profiling-Services/SelectScreen-Profiling-Service/ SelectScreen-Kinase-Profiling-Service.html (accessed Sep 21, 2012).
57. Khopde, S. M.; Priyadarsini, K. I.; Palit, D. K.; Mukherjee, T. Effect of solvent on the excited-state photophysical properties of curcumin Photochem. Photobiol. 2000, 72, 625-631
58. Maestro; Schrödinger, LLC: New York, NY, 2009; http://www. schrodinger.com/products/14/12/ (accessed Sep 20, 2012).
59. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shaw, D. E.; Shelley, M.; Perry, J. K.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749
60. Schrödinger, LLC, New York, NY: http://www.schrodinger.com/products/ 14/5/ (accessed Sep 20, 2012).